METHODS	This study randomly assigned patients with relapsed SCLC not considered as candidates for standard intravenous therapy to best supportive care ( BSC ) alone ( n = 70 ) or oral topotecan ( 2.3 mg/m2/d , days 1 through 5 , every 21 days ) plus BSC ( topotecan ; n = 71 ) .\